Diabetes

1.    Maier R et al. Multiplex bead analysis of vitreous and serum concentrations of inflammatory and proangiogenic factors in diabetic patients. Mol Vis 2008; 14:637-43.
2.    Devendra D et al. Interferon alpha--a potential link in the pathogenesis of viral-induced type 1 diabetes and autoimmunity. Clin Immunol 2004;111:225-33.
3.    Tsiavou A et al. Intracellular IFN-gamma production and IL-12 serum levels in latent autoimmune diabetes of adults (LADA) and in type 2 diabetes. J Interferon Cytokine Res 2004;24:381-7.
4.    Pérez F et al. Plasma levels of interleukin-1beta, interleukin-2 and interleukin-4 in recently diagnosed type 1 diabetic children and their association with beta-pancreatic autoantibodies. Rev Med Chil 2004;132:413-20.
5.    Heitmeier MR et al. Pancreatic beta-cell damage mediated by beta-cell production of interleukin-1. A novel mechanism for virus-induced diabetes. J Biol Chem 2001;276:11151-8.
6.    Srinivasan S et al. Glucose regulates interleukin-8 production in aortic endothelial cells through activation of the p38 mitogen-activated protein kinase pathway in diabetes. J Biol Chem 2004;279:31930-6.
7.    Tesch GH. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. Am J Physiol Renal Physiol 2008;294:F697-701.
8.    Rector RS et al. Exercise and diet induced weight loss improves measures of oxidative stress and insulin sensitivity in adults with characteristics of the metabolic syndrome. Am J Physiol Endocrinol Metab 2007;293:E500-6.
9.    Secchiero P et al. An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am J Pathol 2006;169:2236-44.
10.    Peterson MC. Circulating transforming growth factor beta-1: a partial molecular explanation for associations between hypertension, diabetes, obesity, smoking and human disease involving fibrosis. Med Sci Monit 2005;11:RA229-32.
11.    You S et al. Transforming growth factor-beta and T-cell-mediated immunoregulation in the control of autoimmune diabetes. Immunol Rev 2006;212:185-202.
12.    Alexandraki K et al. Inflammatory process in type 2 diabetes: The role of cytokines. Ann N Y Acad Sci 2006;1084:89-117.
13.    Di Cesare E et al. High serum levels of soluble CD8 in insulin-dependent diabetes. Clin Exp Immunol 1994;95:283-6.
14.    Martinuzzi E et al. Measurement of CD8 T cell responses in human type 1 diabetes. Ann N Y Acad Sci 2008;1150:61-7.
15.    Lyon CJ et al. Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease. Am J Med 2003;115 Suppl 8A:62S-68S.
16.    Brazionis L et al. Plasminogen activator inhibitor-1 activity in type 2 diabetes: a different relationship with coronary heart disease and diabetic retinopathy. Arterioscler Thromb Vasc Biol 2008;28:786-91.
17.    Azar ST et al. Altered plasma levels of nerve growth factor and transforming growth factor-beta2 in type-1 diabetes mellitus. Brain Behav Immun 1999;13:361-6.
18.    Sahli D et al. Tissue plasminogen activator (tPA) activity is a novel and early marker of asymptomatic LEAD in type 2 diabetes. Thromb Res 2009;123:701-6.
19.    Eliasson MC et al. High levels of tissue plasminogen activator (tPA) antigen precede the development of type 2 diabetes in a longitudinal population study. The Northern Sweden MONICA study. Cardiovasc Diabetol 2003;2:19.
20.    Baba K et al. Involvement of apoptosis in patients with diabetic nephropathy: A study on plasma soluble Fas levels and pathological findings. Nephrology (Carlton) 2004;9:94-9.
21.    Hubold C et al. High plasma VEGF relates to low carbohydrate intake in patients with type 2 diabetes. Int J Obes (Lond) 2006;30:1356-61.
22.    Hu G et al. Association of Serum C-Reactive Protein Level with Sex-Specific Type 2 Diabetes Risk: A Prospective Finnish Study. J Clin Endocrinol Metab 2009. [Epub ahead of print]
23.    Cipollone F et al. Enhanced soluble CD40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activation in patients with diabetes mellitus: effect of improved metabolic control. Diabetologia 2005;48:1216-24.
24.    Mirończuk K et al. Interleukin 18 and sICAM-1 serum levels in families with type 1 diabetes mellitus. Rocz Akad Med Bialymst 2005;50:151-4.